EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The diagnostic and prognostic value of tau‐PET in amnestic MCI with different FDG‐PET subtypes

Cecilia Boccalini iD, Silvia Paola Caminiti iD, Arturo Chiti, Giovanni B Frisoni, Valentina Garibotto, Daniela Perani iD, Alzheimer's Disease Neuroimaging Initiative

Annals of Clinical and Translational Neurology · 2024

DOI: 10.1002/acn3.52039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Cecilia Boccalini und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vita-Salute San Raffaele University, Milan, Italy. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Cognitive Dysfunction, tau Proteins, Fluorodeoxyglucose F18. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, Swiss National Science Foundation, Horizon 2020 Framework Programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Mild cognitive impairment presenting with an amnestic syndrome (aMCI) and amyloid positivity is considered due to AD. Many subjects, however, can show an overall very slow progression relevant for differential diagnosis, prognosis, and treatment. This study assessed PET biomarkers, including brain glucose metabolism, tau, and amyloid load, in a series of comparable aMCI at baseline, clinically evaluated at follow‐up.

Methods

We included 72 aMCI subjects from Geneva Memory Center ( N = 31) and ADNI cohorts ( N = 41), selected based on available FDG‐PET, tau‐PET, amyloid‐PET, and clinical follow‐up (2.3 years ± 1.2). A data‐driven algorithm classified brain metabolic patterns into subtypes that were then compared for clinical and PET biomarker measures and cognitive decline. Voxel‐wise comparisons were performed both with FDG‐PET and tau‐PET data.

Results

The algorithm classified three metabolic subtypes, namely “Hippocampal‐sparing with cortical hypometabolism” (Type1; N = 27), “Hippocampal and cortical hypometabolism” (Type 2; N = 23), and “Medial temporal hypometabolism” (Type 3; N = 22). Amyloid positivity and tau accumulation in the medial temporal and neocortical regions characterized Type 1 and Type 2, whereas Type 3 showed no significant tau pathology, variable amyloid positivity, and stability at follow‐up. All tau‐positive patients, independently of the FDG‐based subtype, showed faster cognitive decline. Interpretation aMCI subjects can differ in metabolic patterns, tau and amyloid pathology, and clinical progression. Here, we complemented with PET tau biomarker the specific brain hypometabolic patterns at the individual level in the prodromal phase, contributing to the patient's classification. Tau PET is the most accurate biomarker in supporting or excluding the AD diagnosis in aMCI across metabolic subtypes and also predicting the risk of decline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyCognitive Dysfunctiontau ProteinsFluorodeoxyglucose F18AmnesiaHumansMaleFemaleAgedPrognosisAged, 80 and overMiddle AgedDisease ProgressionBrainBiomarkersAlzheimer DiseaseFollow-Up Studies

Substanzen

tau ProteinsFluorodeoxyglucose F18Biomarkers

Autor:innen und Institutionen

  • Vita-Salute San Raffaele University, Milan, Italy.
  • Laboratory of Neuroimaging and Innovative Molecular Tracers (NIMTlab), Geneva University Neurocenter and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
  • Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy.
  • Nuclear Medicine Department, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland.
  • Memory Clinic, Geneva University Hospitals, Geneva, Switzerland.

ORCID-Profile: Cecilia Boccalini, Silvia Paola Caminiti, Daniela Perani

Förderung

  • NIA NIH HHS
  • Swiss National Science Foundation
  • Horizon 2020 Framework Programme
  • Innovative Medicines Initiative
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
  • Velux Stiftung

Zitieren

APA

Boccalini, C., Caminiti, S. P., Chiti, A., Frisoni, G. B., Garibotto, V., Perani, D., & Alzheimer's Disease Neuroimaging Initiative (2024). The diagnostic and prognostic value of tau‐PET in amnestic MCI with different FDG‐PET subtypes. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52039

Vancouver

Boccalini C, Caminiti SP, Chiti A, Frisoni GB, Garibotto V, Perani D, et al. The diagnostic and prognostic value of tau‐PET in amnestic MCI with different FDG‐PET subtypes. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52039

BibTeX
@article{Boccalini2024,
  author = {Boccalini, Cecilia and Caminiti, Silvia Paola and Chiti, Arturo and Frisoni, Giovanni B and Garibotto, Valentina and Perani, Daniela and Alzheimer's Disease Neuroimaging Initiative, Alzheimer's Disease Neuroimaging Initiative},
  title = {The diagnostic and prognostic value of tau‐PET in amnestic MCI with different FDG‐PET subtypes},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  doi = {10.1002/acn3.52039}
}
Kostenlos starten →